Clinical Studies
Canary-supported studies investigate active surveillance, inherited-risk screening, and imaging technologies. Explore the research questions and the teams' published progress reports.
From research questions to clinical evidence
Clinical research helps teams evaluate promising approaches to cancer detection and management. These summaries draw on the prostate and pancreas teams' July 2026 reports; each links to the report for further detail.
What is the Canary PASS study?
The Prostate Active Surveillance Study (PASS) follows men with early-stage, low-risk prostate cancer who choose active surveillance. The research studies how to distinguish favorable-risk cancers from aggressive disease and support decisions about treatment.
Read the July 2026 PASS research updateWhat is the Canary PATROL study?
PATROL studies prostate cancer screening for men with inherited risk of aggressive disease. The team is investigating how imaging, biomarkers, and PSA thresholds can inform screening and biopsy decisions for this population.
Read the July 2026 PATROL research updateHow is pancreatic imaging being studied?
The pancreas team is evaluating handheld point-of-care ultrasound, contrast enhancement with microbubbles, and quantitative ultrasound. Clinical trials compare pancreatic imaging with endoscopic ultrasound and investigate new ways to assess tissue characteristics.
Read the July 2026 pancreas research updateHow do PASS and PATROL differ?
PASS follows men already diagnosed with early-stage, low-risk prostate cancer who choose active surveillance. PATROL focuses on screening men with inherited risk of aggressive prostate cancer. They address different questions: monitoring a diagnosed cancer and screening a population at genetic risk.